Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CR011-vcMMAE in Advanced Melanoma
NCT00412828Phase 2Completed
- Sponsor
- CuraGen Corporation
- Start
- Jun 2006
- Primary completion
- Dec 2010
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glembatumumab vedotin in melanoma, sponsored by CuraGen Corporation. Primary endpoints: Maximum Tolerated Dose and Dose-Limiting Toxicities. Started Jun 2006; status: completed.
02
Drugs
glembatumumab vedotin
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00412828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00412828.